Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
WALTHAM, Mass., March 01, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Cowen and Company Annual Health Care Conference
Monday, March 6, 2017 at 2:40 p.m. ET
Location: Boston, MA
- Raymond James Annual Institutional Investors Conference
Wednesday, March 8, 2017 at 10:25 a.m. ET
Location: Orlando, FL
- Barclays Global Healthcare Conference
Tuesday, March 14, 2017 at 2:35 p.m. ET
Location: Miami, FL
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
